Chabiotech Co.,Ltd.

KOSDAQ:A085660 Stock Report

Market Cap: ₩856.0b

ChabiotechLtd Valuation

Is A085660 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A085660 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate A085660's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A085660's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for A085660?

Key metric: As A085660 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for A085660. This is calculated by dividing A085660's market cap by their current revenue.
What is A085660's PS Ratio?
PS Ratio0.8x
Sales₩1.01t
Market Cap₩855.98b

Price to Sales Ratio vs Peers

How does A085660's PS Ratio compare to its peers?

The above table shows the PS ratio for A085660 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average4.9x
A067630 HLB Life Science
12.8xn/a₩1.2t
A008930 Hanmi Science
1.7xn/a₩2.2t
A078160 MEDIPOST
4.1xn/a₩284.0b
A145720 Dentium
1.2x11.5%₩482.9b
A085660 ChabiotechLtd
0.8xn/a₩856.0b

Price-To-Sales vs Peers: A085660 is good value based on its Price-To-Sales Ratio (0.8x) compared to the peer average (4.9x).


Price to Sales Ratio vs Industry

How does A085660's PS Ratio compare vs other companies in the Asian Healthcare Industry?

61 CompaniesPrice / SalesEstimated GrowthMarket Cap
A085660 0.8xIndustry Avg. 1.6xNo. of Companies65PS01.63.24.86.48+
61 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: A085660 is good value based on its Price-To-Sales Ratio (0.8x) compared to the Asian Healthcare industry average (1.6x).


Price to Sales Ratio vs Fair Ratio

What is A085660's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A085660 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.8x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate A085660's Price-To-Sales Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies